Celularity Inc. Class A Common Stock
CELUCelularity Inc. Class A (CELU) is a biotechnology company that specializes in the development of cellular therapies derived from placental cells. Focused on regenerative medicine and immunotherapy, the company aims to create treatments for a variety of medical conditions, including cancer, infectious diseases, and degenerative disorders, leveraging the unique properties of placental stem cells.
Company News
Celularity Inc. received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report on Form 10-Q for Q1 2026. The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Trading of the stock continues una...
NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focuse...
Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.
Celularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.
Celularity Inc. (CELU) received a Nasdaq delisting notice due to unpaid fees and a delinquent SEC filing. The company paid the outstanding fees and is working to file the 2024 Form 10-K.
